Table 3

Effect of exisulind, docetaxel, and the combination on the number of athymic rats with metastases from orthotopic A549 tumors (second experiment)

TreatmentDose and scheduleMean survival days (P, log-rank)# rats with mets/# treated (P, Fisher’s exact test)
Control35.7 days15/15
Exisulind25 mg/kg daily36 days12/12
(P = 0.76)(P = 1.0)
Exisulind50 mg/kg daily41.08 days11/12
(P = 0.31)(P = 0.41)
Docetaxel2.5 mg/kg/wk (6×)34.5 days12/12
(P = 0.66)(P = 1.0)
Docetaxel5 mg/kg/wk (6×)43.58 days9/12
(P = 0.17)(P = 0.06)
Exisulind25 mg/kg daily35.5 days12/12
Docetaxel2.5 mg/kg/wk (6×)(P = 0.68)(P = 1.0)
Exisulind25 mg/kg daily49.33 days8/12
Docetaxel5 mg/kg/wk (6×)(P = 0.04)(P = 0.02)
Exisulind50 mg/kg daily36 days11/12
Docetaxel2.5 mg/kg/wk (6×)(P = 0.31)(P = 0.41)
Exisulind50 mg/kg daily63.17 days2/12
Docetaxel5 mg/kg/wk (6×)(P < 0.0004)(P < 0.0001)
Exisulind50 mg/kg daily65.17 days1/12
Docetaxela5 mg/kg/wk (3×)(P < 0.0001)(P < 0.0001)
2.5 mg/kg/wk (3×)
  • a Docetaxel was administered at 5 mg/kg/wk for the weeks 1–3 and at the lower dose of 2.5 mg/kg/wk for weeks 4–6.